World Journal of Endocrine Surgery

Register      Login

VOLUME 13 , ISSUE 3 ( September-December, 2021 ) > List of Articles


Survival and Prognosis of Anaplastic Thyroid Cancer: A 15-year Observation at a Single Asian Institute

Sarah I Liew, Nor S Ahmad, Sarinah Basro, Anita Baghawi, Noor H Abdullah

Keywords : Anaplastic thyroid cancer, Multidisciplinary approach, Outcomes, Treatments

Citation Information : Liew SI, Ahmad NS, Basro S, Baghawi A, Abdullah NH. Survival and Prognosis of Anaplastic Thyroid Cancer: A 15-year Observation at a Single Asian Institute. World J Endoc Surg 2021; 13 (3):97-101.

DOI: 10.5005/jp-journals-10002-1416

License: CC BY-NC 4.0

Published Online: 19-05-2022

Copyright Statement:  Copyright © 2021; The Author(s).


Aim: Limited literature from Southeast Asia (SEA) exists on anaplastic thyroid cancer (ATC). The aim of this study was to ascertain factors associated with the survival of ATC at Putrajaya Hospital which is the main referral center for endocrine cases in West Malaysia. Materials and methods: This is a retrospective analysis of all patients with ATC between January 2002 and December 2016. Data concerning comorbidities, stage of disease, and clinical course were collected via electronic medical records and analyzed with Kaplan-Meier survival and log-rank tests for univariate and Cox proportional hazards model for multivariate analysis. This study was approved by the Malaysian Medical Research Ethics Committee (MREC). Results: A total of 76 patients were treated for ATC at our center, however, 11 had missing data and were excluded from the analysis. Of the remaining 65 patients, the majority were women (44 cases), and the mean age at presentation was 62 years. Majority of patients presented with stage IV C (50.8%) whilst others presented with IV A (3.1%) and IV B (46.2%). Most patients were treated palliatively (36.9%) whilst 29.2% underwent surgery only, 16.9% radiotherapy only, and 16.9% had multimodal therapies. Median survival was 2 months (range 1–14 months) with survival rates of 7.7–1.5% at 6 months and 1-year, respectively. Univariate analysis demonstrated that stage of disease and combination therapy improved survival. When correction was made for sex, age, and stage of disease, the only type of treatment received significantly affected outcomes. Multimodal therapy, either surgery and radiotherapy (hazard ratio 0.29, confidence interval 0.091–0.939, p = 0.03) or surgery followed by radiotherapy and chemotherapy (hazard ratio 0.09, confidence interval 0.01–1.0, p = 0.05) conferred better outcomes. Conclusion: The findings in this study that multimodal therapy conferred improved outcomes were comparable to that of numerous other studies, however, more research is needed in assessing the best treatment for this deadly disease.

  1. Htwe TT, Hamdi MM, Swethadri GK, et al. Incidence of thyroid malignancy among goitrous thyroid lesions from the Sarawak general hospital 2000-2004. Singapore Med J 2009;50(7):724–728. PMID: 19644631.
  2. Othman NH, Omar E, Naing NN. Spectrum of thyroid lesions in hospital Universiti Sains Malaysia over 11years and a review of thyroid cancers in Malaysia. Asian Pac J Cancer Prev 2009;10(1):87–90. PMID: 19469631.
  3. Tuttle RM, Haugen B, Perrier ND. Updated American joint committee on cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer: what changed and why? Thyroid 2017;27(6):751–756. DOI: 10.1089/thy.2017.0102
  4. Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012;22(11):1104–1139. DOI: 10.1089/thy.2012.0302
  5. Bible KC, Kebebew E, Brierley J, et al. American thyroid association guidelines for management of patients with anaplastic thyroid cancer: American thyroid association anaplastic thyroid cancer guidelines task force. Thyroid 2021;31(3):337–386. DOI: 10.1089/thy.2020.0944
  6. Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 1998;8(8):715–726. DOI: 10.1089/thy.1998.8.715
  7. Lin B, Ma H, Ma M, et al. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am J Transl Res 2019;11(9):5888–5896. PMID: 31632557.
  8. Pacini F, Castagna MG, Brilli L, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(7):vii110–119. DOI: 10.1093/annonc/mds230
  9. Brignardello E, Palestini N, Felicetti F, et al. Early surgery and survival of patients with anaplastic thyroid carcinoma: analysis of a case series referred to a single institution between 1999 and 2012. Thyroid 2014;24(11):1600–1606. DOI: 10.1089/thy.2014.0004
  10. Akaishi J, Sugino K, Kitagawa W, et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 2011;21(11):1183–1189. DOI: 10.1089/thy.2010.0332
  11. Livhits MJ, Yeh MW. Multimodality treatment with surgery, external-beam radiation, and chemotherapy improves survival for selected patients with anaplastic thyroid cancer. Clin Thyroidol 2017;29(3): 90–93. DOI: 10.1089/ct.2017;29.90-93
  12. Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 2011;21(1):25–30. DOI: 10.1089/thy.2010.0220
  13. Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma: treatment outcome and prognostic factors. Cancer 2005;103(7):1330–1335. DOI: 10.1002/cncr.20936
  14. Liu TR, Xiao ZW, Xu HN, et al. Treatment and prognosis of anaplastic thyroid carcinoma: a clinical study of 50 cases. PLoS One 2016;11(10):e0164840. DOI: 10.1371/journal.pone.0164840
  15. Crevoisier RD, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004;60(4):1137–1143. DOI: 10.1016/j.ijrobp.2004.05.032
  16. Besic N, Auersperg M, Us-Krasovec M, et al. Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol 2001;27(3):260–264. DOI: 10.1053/ejso.2000.1098
  17. Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 2002;86(12):1848–1853. DOI: 10.1038/sj.bjc.6600361
  18. Higashiyama T, Ito Y, Hirokawa M, et al. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 2010;20(1):7–14. DOI: 10.1089/thy.2009.0115
  19. Onoda N, Sugino K, Higashiyama T, et al. The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients: a nationwide prospective study. Thyroid 2016;26(9):1293–1299. DOI: 10.1089/thy.2016.0072
  20. Giuffrida D, Gharib H. Anaplastic thyroid carcinoma: current diagnosis and treatment. Ann Oncol 2000;11(9):1083–1090. DOI: 10.1023/a:1008322002520
  21. Besic N, Hocevar M, Zgajnar J. Lower incidence of anaplastic carcinoma after higher iodination of salt in Slovenia. Thyroid 2010;20(6):623–626. DOI: 10.1089/thy.2009.0404
  22. Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol 2010;22(6): 486–497. DOI: 10.1016/j.clon.2010.03.013
  23. Rao SN, Zafereo M, Dadu R, et al. Patterns of treatment failure in anaplastic thyroid carcinoma. Thyroid 2017;27(5):672–681. DOI: 10.1089/thy.2016.0395
  24. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015;373(8):726–736. DOI: 10.1056/NEJMoa1502309
  25. Iñiguez-Ariza NM, Ryder MM, Hilger CR, et al. Salvage lenvatinib therapy in metastatic anaplastic thyroid cancer. Thyroid 2017;27(7):923–927. DOI: 10.1089/thy.2016.0627
  26. Ha HT, Lee JS, Urba S, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 2010;20(9): 975–980. DOI: 10.1089/thy.2010.0057
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.